Download Pre-stems - World Health Organization

_
INN Working Document 06.186/P
Distr.: GENERAL
ENGLISH ONLY
24/04/2006
Pre-stems*:
Suffixes used in the selection of INNs
April 2006
© World Health Organization (2006)
This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The
document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written
permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any
means - electronic, mechanical or other - without the prior written permission of WHO.
The views expressed in documents by named authors are solely the responsibility of those authors.
*The prestems given have been flagged because they may be selected as official stems ("The use of stems in the selection of
International Nonproprietary Names) for pharmaceutical substances", WHO/EDM/QSM/2004.5). At present, they are made
available for information and potential guidance to the applicants.
1
stem
definition
-suffix
-infixxxxxx
new stems or (*) change to already existing stem definition
newly selected prestems
xxxxx
_________________________________________________________________________
-algron
α1-adrenoreceptor agonists
-ampanel*
antagonists of the ionotropic non-NMDA (N-methyl-Dasparate) glutamate receptors (namely the AMPA and/or KA
receptors (Amino-hydroxy-Methyl-isoxazole-Propionic
Acid and/or kainate))*
-ampator
amino-hydroxymethyl-isoxazole-propionic acid (AMPA)
receptor modulators
-ast
antiasthmatics, antiallergics, not acting primarily as
antihistaminics
integrin antagonists
-tegr-axomab
see mab
-bercept
see cept
-berel
beta estrogen receptor agonists
-camra
intracellular adhesion molecule (ICAM)-1 derivatives
-casan
caspase (interleukin-1b) converting enzyme inhibitors
-caserin
serotonin receptor agonists (mostly 5-HT2)
-catib
cathepsin inhibitors
cept
-ber-co-far-lefa-na-ta-vir-ciclib
receptor molecules, native or modified (a preceding infix
should designate the target)
VEGF (Vascular Endothelial Growth Factor) receptors
complement receptors
subgroup of interferon receptors
lymphocyte function-associated antigen 3
interleukin-1
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
antiviral receptors
cyclin dependant kinase inhibitors
2
-ciguat
guanylate cyclase activators
-cocept
see cept
-cridar
see dar
-cri-ico-spo-
drugs used in multidrug resistance
acridinecarboxamide derivatives
pipecolinate derivatives
ciclosporin D derivatives
dar
-depsin
depsipeptide derivatives
-ectedin
ecteinascidin derivatives
-estrant
estrogen antagonists
-farcept
-farnib
-fibatide
see cept
farnesyl transferase inhibitors
see tide
-fulven
antineoplastic, acylfulven derivatives
-ganan
antimicrobial, bactericidal permeability increasing
polypeptides
-gapil
neuronal apoptosis inhibitors, GAPDH (Glyceraldehyde-3phosphate dehydrogenase)
gene
gene therapy products
see last page of this document
gli
antihyperglycaemics
dipeptidyl aminopeptidase–IV inhibitors
-gliptin
-icodar
-imepodib
-imidar
imod
-mapimod
see dar
inosine monophosphate dehydrogenase inhibitors
see dar
immunomodulators, both stimulant/suppressive and
stimulant
mitogen-activated protein (MAP) kinase inhibitors
3
imus
-rolimus
immunosuppressants (other than antineoplastics)
immunosuppressants, rapamycin derivatives
-isant
histamine H3 receptor antagonists
-kalner
openers of calcium-activated (maxi-K) K+-channels
-lefacept
see cept
-leptin(e)
leptin derivatives
-lutamide
non-steroid antiandrogens
-lutril
see tril/trilat
-axo-os-
monoclonal antibodies
rat-murine hybrid antibodies
bone
-mapimod
see imod
mab
-moren
non-peptidic growth hormone secretagogues
-mulin
antibacterials, pleuromulin derivatives
-nacept
see cept
-nesib
kinesin inhibitors
-neurin
neurotrophins
-punil
benzodiazepine receptor antagonists/agonists
mitochondrial benzodiazepine receptor (MBR)- selective
agonists also partial or inverse (purine derivatives)
-osuran
urotensin receptor antagonists
-otilate
hepatoprotectants, diisopropyl-1,3-dithiol-malonate
derivatives
-parib
Poly-ADP-Ribose polymerase inhibitors
-peg/-pegil ?
is to be considered for future pegylated compounds (i.e.
substances linked covalently to polyethylene glycol)
-plasinin
inhibitors of plasminogen activator inhibitors-type 1 (PAI-1)
nil
4
-plasmid
gene therapy products
please refer to last page of this document
-prazan
proton pump inhibitors, not depended on acid activation
-pris-
steroidal compounds acting on progesterone receptors
(excluding -gest- compounds)
-prinim
nootropic agents, purine derivatives
-punil
see nil
-rolimus
see -imus
-spodar
see dar
-siban
oxytocin antagonists
-sulind
antineoplastics, sulindac metabolites
-stinel
(N-methyl-D-asparate) NMDA receptor antagonist, glycine
recognition site
-tacept
-tapide
-tegrast
-texafin
tide
-fiba-
see -cept
microsomal triglyceride transfer protein (MTP) inhibitors
see ast
texaphyrin derivatives
peptides and glycopeptides
platelet aggregation inhibitor (GPIIb/IIIa receptor
antagonist)
-tirome
antihyperlidaemic; thyrominetic derivatives
-trombopag
thrombopoietin agonists
tril/trilat
-lutril
-uclin
vec
endopeptidase inhibitors
neutral endopeptidase inhibitors possessing additional
endothelin converting enzyme inhibitory activity
mucosal tolerance inductors
gene therapy products
please refer to last page of this document
5
vir
-virenz
-viroc
antivirals (undefined group)
benzoxazinone derivatives
Cystein-Cystein type chemokine receptor 5 (CCR5)
antagonists
-vircept
see cept
-virenz
see vir
-viroc
see vir
6
Gene therapy products:
A two-word name approach has been selected:
Word 1
-gene
gene component
immunomodulators
tumour suppression
growth factors
interleukins
multiple genes
-lim(o)-tusu-ermin(o)-kin(o)-mulprefix
random to contribute to
euphonious and distinctive
name
Word 2
-lim(o)-tusu-ermin(o)-kin(o)-muletc.
-vec
-lenti-retro-adeno-vari-cana-herpa-plasmid
prefix
-lenti-retrorandom to contribute -adenoto euphonious and
-varidistinctive name
-cana-herpa-
infix
immunomodulators
tumour suppression
growth factors
interleukins
multiple genes
suffix
-gene
vector component is a virus
lentiviruses
other retroviruses
adenoviruses
vacciniae
canarypox viruses
herpes viruses
in case the vector is a plasmid
infix
lentiviruses
other retroviruses
adenoviruses
vaccinia viruses
canarypox viruses
herpes viruses
suffix
-vec
virus
-plasmid
plasmid
In case of naked DNA, there is no need for a second word in the name.
In case of antisense nucleotides, please refer to the already existing stem -rsen
(WHO/EDM/QSM/2004.5, Addendum 1).
***
7